Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexanone SCHEMBL3835265 | 0.86 | LMNA (0.48) | LMNABCHEACHEPTGS2 | |
| Ethylene SCHEMBL140298 | 0.83 | LMNA (0.55) | LMNABCHEACHEPTGS2 | |
| Cyclohexanone SCHEMBL6517734 | 0.81 | LMNA (0.52) | LMNABCHEACHEPTGS2 | |
| SCHEMBL2698061 | 0.80 | LMNA (0.63) | LMNABCHEACHEPTGS2 | |
| Ethylene SCHEMBL4424062 | 0.79 | LMNA (0.50) | LMNABCHEACHEPTGS2 | |
| Ethylene SCHEMBL4935788 | 0.77 | LMNA (0.75) | LMNA | |
| Ethylene SCHEMBL555416 | 0.76 | LMNA (0.86) | LMNA | |
| Ethylene SCHEMBL3362390 | 0.76 | LMNA (0.86) | LMNA | |
| Ethylene SCHEMBL9049781 | 0.75 | LMNA (0.44) | LMNA | |
| Ethylene SCHEMBL3959533 | 0.75 | LMNA (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105755846-B | A kind of water suction Breathable artificial leather and preparation method thereof | 江苏盈泰新材料科技有限公司 | 2018-11-13 | — | — | CN | claimed |
| CN-107827721-A | A kind of method for synthesizing 4 fluorine cyclohexanone | 上海恩氟佳科技有限公司 | 2018-03-23 | — | — | CN | claimed |
| US-20240059672-A1 | METHOD OF PREPARING PRALSETINIB | BLUEPRINT MEDICINES CORPORATION | 2024-02-22 | — | — | US | disclosed |
| EP-4255892-A1 | METHOD OF PREPARING PRALSETINIB | Blueprint Medicines Corporation (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-116724024-A | Process for preparing platinib | 缆图药品公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4019491-A1 | PROCESS FOR PREPARING A SYNTHETIC INTERMEDIATE USEFUL IN THE PREPARATION OF AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022120136-A1 | METHOD OF PREPARING PRALSETINIB | BLUEPRINT MEDICINES CORPORATION (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-3954687-A1 | PROCESSES AND INTERMEDIATES USEFUL IN THE PREPARATION OF AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2022-02-16 | — | — | EP | disclosed |
| EP-3569588-A1 | PROCESS FOR PREPARING A SYNTHETIC INTERMEDIATE USEFUL IN THE PREPARATION OF AN APOPTOSIS-INDUCING AGENT | AbbVie Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| CN-107001371-B | Oxipurinol class compound and its application | 广东众生睿创生物科技有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-105755846-B | A kind of water suction Breathable artificial leather and preparation method thereof | 江苏盈泰新材料科技有限公司 | 2018-11-13 | — | — | CN | disclosed |
| CN-102532149-A | Asymmetric synthesis method for galanthamine and lycoramine | UNIV NANKAI | 2012-07-04 | — | — | CN | disclosed |
| CN-102532149-A | Asymmetric synthesis method for galanthamine and lycoramine | UNIV NANKAI | 2012-07-04 | — | — | CN | disclosed |
| EP-2220081-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG Life Sciences Ltd. (KR) | 2010-08-25 | — | — | EP | disclosed |
| EP-2183245-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009082152-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009013212-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| CN-1130670-A | Liquid crystalline compound containing fluorine atom substituted alkyl group(s) and a liquid crystal composition | CHISSO CORP (JP) | 1996-09-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059672-A1 | METHOD OF PREPARING PRALSETINIB | PCSK9, NRAS, LPXN | LMNA 343/4885BCHE 2667/4885ACHE 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.